Physician profile
Mark R Ogle
NPI 1801842422
$5,171.61
in general payments reported to CMS, 2019-2025
30 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $686 · 2021: $764 · 2022: $848 · 2023: $728 · 2024: $492 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,065.21 | 2021-2025 | |
| Allergan, INC. | $502.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $438.93 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $432.49 | 2019-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $390.21 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $350.71 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.63 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $265.44 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $197.57 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $177.23 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $127.98 | 2019-2022 | |
| Eisai INC. | $113.39 | 2020-2021 | |
| Axsome Therapeutics, INC. | $87.30 | 2023-2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $86.00 | 2021-2022 | |
| Corium, LLC | $84.04 | 2022-2025 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $81.51 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $66.89 | 2019 | |
| Avanir Pharmaceuticals, INC. | $60.36 | 2019-2020 | |
| Alkermes, INC. | $58.56 | 2019-2024 | Aristada, Lybalvi |
| Neos Therapeutics, Lp | $49.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $48.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.03 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $31.75 | 2023-2024 | Qelbree, Qelbree |
| Owp Pharmaceuticals, INC. | $31.42 | 2019 | |
| Adlon Therapeutics L.P. | $28.17 | 2020 | |
| Almatica Pharma LLC | $19.19 | 2025 | Loreev Xr |
| Sun Pharmaceutical Industries INC. | $16.14 | 2020 | |
| Shire North American Group INC | $12.94 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.73 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.